Abstract

Tissue equivalents produced using bioengineering technologies are emerging as robust and versatile cellular assay platforms for drug discovery and development.  Bioengineering technologies enable the production of spatially controlled tissues with tailored physiological complexity using iPSC-derived or primary cells, in multi-well plate platforms amenable for medium throughput screening.

Operationalization of the use of bioengineered 3D organotypic models with existing automation screening platforms meets with challenges in cell production, reproducible tissue biofabrication in multi-well plate format, 3D phenotypic assays, and data generation and processing challenges.  Examples of bioengineered tissue models and their use for drug screening will be discussed.